The IPO Buzz: Coya Therapeutics (COYA) Slips in its NASDAQ Debut

Coya Therapeutics Inc. (COYA) declined Thursday (Dec. 29, 2022) in its NASDAQ debut – opening at $4.75, down 25 cents or 5 percent from its $5.00 IPO price. The Houston biotech’s stock later slipped to $4.59, down 8.2 percent from its IPO price. Coya Therapeutics’ stock closed its first day of trading at $4.57, down 43 cents or 8.6 percent below its IPO price – technically a broken deal.

Coya Therapeutics priced its tiny unit IPO – 3.05 million shares and non-listed warrants to buy up to 1.5 million shares at $5.00 per unit – in line with the terms in its prospectus – on Wednesday night (Dec. 28, 2022) to raise $15.25 million.

Chardan and Newbridge Securities were the joint book-runners.

Coya Therapeutics’ IPO looks likely to be the last IPO priced in 2022. This year is deemed to be among the worst periods for IPOs in about 20 years.

In its prospectus, clinical biotech Coya Therapeutics says it is “focused on developing proprietary new therapies to enhance the function of regulatory T cells (“Tregs”). “

The cells in Tregs are a subset of T-lymphocytes, a type of white blood cell that suppresses inflammatory responses, the prospectus says.

“We are initially focused on developing our Treg-based therapies for neurodegenerative, autoimmune and metabolic diseases where Treg dysfunction has been identified to be an important pathophysiological component of the disease and where new and effective therapies are urgently needed,” the prospectus says.

Coya Therapeutics Inc. is not profitable, which is usually the case when a biotech goes public. The company reported a net loss of $10.8 million on no revenue for the 12 months that ended Sept. 30, 2022.

Prestige Wealth Management (PWM proposed), a Hong Kong-based wealth management and asset management firm, postponed its IPO on Thursday. Some see this IPO being revived in 2023.

A few other tiny IPOs on this week’s calendar have been rolled forward to early January, with pricing dates pending regulatory approval.

Stay tuned.

(For more information about this company, please check the IPO Calendar and the individual IPO Profiles found on’s website.)

Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.

To see what time the NASDAQ IPOs are expected to trade, please log in to: then scroll down to IPO Message.

Disclosure: Nobody on the staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The staff does not issue advice, recommendations or opinions.

Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.